Interleukin-21 Enhances Rituximab Activity in a Cynomolgus Monkey Model of B Cell Depletion and in Mouse B Cell Lymphoma Models

• Cecile M. Krejsa,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Rick D. Holly,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Mark Heipel,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Ken M. Bannink,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Rebecca Johnson,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Richard Roque,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Jane Heffernan,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Julie Hill,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Lay Chin,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Felecia Wagener,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Faith Shiota,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Katherine Henderson,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Pallavur V. Sivakumar,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Hong-Ping Ren,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Fariba Barahmand-pour,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Don Foster,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Chris Clegg,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Wayne Kindsvogel,

  Affiliation Department of Research, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Rafael Ponce,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• Steven D. Hughes,

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
•  [ ... ],
• Kim Waggie

  * E-mail: Kim.Waggie@bms.com

  Affiliation Department of Pre-clinical Development, ZymoGenetics, Incorporated, a Bristol-Myers Squibb Company, Seattle, Washington, United States of America

  ⨯
• [ view all ]
• [ view less ]